We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Equifax (EFX) in Your Portfolio
Read MoreHide Full Article
Equifax Inc.’s (EFX - Free Report) shares have charted a solid trajectory in recent times, appreciating a massive 66.5% over the past year, ahead of the industry’s gain of 58.2%.
The company has an impressive Growth Score of A. This style score condenses all the essential metrics from a company’s financial statements to get a true sense of quality and sustainability of its growth.
Equifax has an expected long-term earnings per share (three to five years) growth rate of 13.1%. Its revenues are expected to increase 7.8% in 2021 and 6% in 2022, year over year.
Factors That Auger Well
Equifax is benefiting from a solid product portfolio and clear understanding of the sectors it serves. Customers find considerable significance in the company’s offerings as they use the credit information and related analytical services and data to process applications for new credit cards, automobile loans, home and equity loans, and other consumer loans.
We believe synergies from acquisitions, in addition to continued general consumer credit activity, product innovation, initiatives to foster enterprise growth, and efficient business executions, will continue to boost Equifax’s revenues over the long run. Revenues have shown decent growth rates in the past few years, having grown at a CAGR of 5.6% from 2016 to 2020. The top line improved 23.5% year over year in the fourth quarter of 2020.
Debt Woes Stay
Equifax’s total debt at the end of fourth-quarter 2020 was $3.28 billion, flat sequentially. The company’s cash and cash equivalent of $1.68 billion at the end of the quarter was well below this debt level, underscoring that the company doesn’t have enough cash to meet this debt burden. The cash level, however, can meet the short-term debt of $1.1 billion.
The long-term expected earnings per share (three to five years) growth rate for Interpublic, Cross Country Healthcare and Charles River is pegged at 2.4%, 12% and 13%, respectively.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Here's Why You Should Retain Equifax (EFX) in Your Portfolio
Equifax Inc.’s (EFX - Free Report) shares have charted a solid trajectory in recent times, appreciating a massive 66.5% over the past year, ahead of the industry’s gain of 58.2%.
The company has an impressive Growth Score of A. This style score condenses all the essential metrics from a company’s financial statements to get a true sense of quality and sustainability of its growth.
Equifax has an expected long-term earnings per share (three to five years) growth rate of 13.1%. Its revenues are expected to increase 7.8% in 2021 and 6% in 2022, year over year.
Factors That Auger Well
Equifax is benefiting from a solid product portfolio and clear understanding of the sectors it serves. Customers find considerable significance in the company’s offerings as they use the credit information and related analytical services and data to process applications for new credit cards, automobile loans, home and equity loans, and other consumer loans.
We believe synergies from acquisitions, in addition to continued general consumer credit activity, product innovation, initiatives to foster enterprise growth, and efficient business executions, will continue to boost Equifax’s revenues over the long run. Revenues have shown decent growth rates in the past few years, having grown at a CAGR of 5.6% from 2016 to 2020. The top line improved 23.5% year over year in the fourth quarter of 2020.
Debt Woes Stay
Equifax’s total debt at the end of fourth-quarter 2020 was $3.28 billion, flat sequentially. The company’s cash and cash equivalent of $1.68 billion at the end of the quarter was well below this debt level, underscoring that the company doesn’t have enough cash to meet this debt burden. The cash level, however, can meet the short-term debt of $1.1 billion.
Zacks Rank and Stocks to Consider
WEX currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Business Services sector are The Interpublic Group of Companies (IPG - Free Report) , Cross Country Healthcare (CCRN - Free Report) and Charles River Associates (CRAI - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The long-term expected earnings per share (three to five years) growth rate for Interpublic, Cross Country Healthcare and Charles River is pegged at 2.4%, 12% and 13%, respectively.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>